Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Study to Investigate the Safety, Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of HLX23 (CD73 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors

NCT04797468 is registered in ClinicalTrials.gov with Shanghai Henlius Biotech as lead sponsor.

NCT NCT04797468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04797468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Study to Investigate the Safety, Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of HLX23 (CD73 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors
Lead sponsor
Shanghai Henlius Biotech
Phase
Phase 1
Overall status
Withdrawn
Start date
July 18, 2022
Completion date
January 13, 2023
Enrollment
0 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor